




Searching News Database: Biogen Idec
HSMN NewsFeed - 17 Oct 2018
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
HSMN NewsFeed - 17 Sep 2018
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
HSMN NewsFeed - 5 Jan 2016
Editas Medicine Expands Leadership Team with Key Organizational Appointments
Editas Medicine Expands Leadership Team with Key Organizational Appointments
HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
HSMN NewsFeed - 10 Oct 2014
Vernalis Opens US Office and Strengthens US Team With the Appointment of SVP Medical Affairs
Vernalis Opens US Office and Strengthens US Team With the Appointment of SVP Medical Affairs
HSMN NewsFeed - 30 Jun 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
HSMN NewsFeed - 14 May 2014
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
HSMN NewsFeed - 9 Apr 2014
CardioDx and Medison Israel Enter Into an Exclusive Corus(R) CAD Product Marketing and Sales Agreement
CardioDx and Medison Israel Enter Into an Exclusive Corus(R) CAD Product Marketing and Sales Agreement
HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
HSMN NewsFeed - 31 Jan 2014
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
HSMN NewsFeed - 10 Sep 2013
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease
HSMN NewsFeed - 26 Jul 2013
Adimab Announces First Antibody Technology Transfer and License Agreement with GlaxoSmithKline
Adimab Announces First Antibody Technology Transfer and License Agreement with GlaxoSmithKline
HSMN NewsFeed - 28 Jun 2013
Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer
Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 18 Dec 2012
Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors
Biogen Executive Kenneth DiPietro Joins InVivo Therapeutics Board of Directors
HSMN NewsFeed - 27 Nov 2012
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
HSMN NewsFeed - 20 Sep 2012
Elan Announces the Appointment of Hans Peter Hasler as Chief Operating Officer
Elan Announces the Appointment of Hans Peter Hasler as Chief Operating Officer
HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
HSMN NewsFeed - 30 Jan 2012
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 3 Mar 2011
Gentium Appoints Adrian Haigh as Senior Vice President of Commercial Operations
Gentium Appoints Adrian Haigh as Senior Vice President of Commercial Operations
HSMN NewsFeed - 18 Jan 2011
ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs
ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs
HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
HSMN NewsFeed - 4 Jan 2011
Momenta Pharmaceuticals Appoints Young T. Kwon as Vice President, Business Development
Momenta Pharmaceuticals Appoints Young T. Kwon as Vice President, Business Development
HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
HSMN NewsFeed - 7 Dec 2010
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
HSMN NewsFeed - 7 Jul 2010
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
HSMN NewsFeed - 22 Feb 2010
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed - 25 Jan 2010
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
HSMN NewsFeed - 20 Jan 2010
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
HSMN NewsFeed - 4 Jan 2010
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
HSMN NewsFeed - 17 Dec 2009
ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
HSMN NewsFeed - 19 Oct 2009
Facet Biotech's Board of Directors Recommends Stockholders Continue to Reject Biogen Idec's Tender Offer
Facet Biotech's Board of Directors Recommends Stockholders Continue to Reject Biogen Idec's Tender Offer
HSMN NewsFeed - 5 May 2009
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 21 Oct 2008
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer
HSMN NewsFeed - 8 Oct 2008
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
HSMN NewsFeed - 2 Sep 2008
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
HSMN NewsFeed - 12 Aug 2008
Stromedix Receives Orphan Drug Designation for STX-100 in Chronic Allograft Nephropathy
Stromedix Receives Orphan Drug Designation for STX-100 in Chronic Allograft Nephropathy
HSMN NewsFeed - 12 Aug 2008
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
HSMN NewsFeed - 27 May 2008
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
HSMN NewsFeed - 17 Apr 2008
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
HSMN NewsFeed - 17 Mar 2008
Zimmer Holdings, Inc. Adds Robert Hagemann and Cecil Pickett to Board of Directors
Zimmer Holdings, Inc. Adds Robert Hagemann and Cecil Pickett to Board of Directors
HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 4 Feb 2008
Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
HSMN NewsFeed - 27 Dec 2007
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
HSMN NewsFeed - 3 Dec 2007
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
HSMN NewsFeed - 8 Nov 2007
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
HSMN NewsFeed - 8 Nov 2007
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
HSMN NewsFeed - 16 Oct 2007
Metastatix Appoints Carol G. Gallagher, Pharm.D. as President and Chief Executive Officer
Metastatix Appoints Carol G. Gallagher, Pharm.D. as President and Chief Executive Officer
HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
HSMN NewsFeed - 19 Sep 2007
Alnylam Announces the Termination of its Collaboration with Merck & Co., Inc.
Alnylam Announces the Termination of its Collaboration with Merck & Co., Inc.
HSMN NewsFeed - 10 Sep 2007
FDA Informs Endo and Vernalis That New Target Action Date on Frova(R) sNDA Is Sept. 30, 2007
FDA Informs Endo and Vernalis That New Target Action Date on Frova(R) sNDA Is Sept. 30, 2007
HSMN NewsFeed - 14 Aug 2007
Phase II Clinical Trial Results for ADENTRI Published in Journal of the American College of Cardiology
Phase II Clinical Trial Results for ADENTRI Published in Journal of the American College of Cardiology
HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
HSMN NewsFeed - 29 Jun 2007
Merck Names Peter Kellogg as Executive Vice President and Chief Financial Officer
Merck Names Peter Kellogg as Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 27 Jun 2007
NUCRYST Pharmaceuticals appoints Katherine J. Turner, PhD to Vice President, Research and Development
NUCRYST Pharmaceuticals appoints Katherine J. Turner, PhD to Vice President, Research and Development
HSMN NewsFeed - 26 Jun 2007
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
HSMN NewsFeed - 11 Jun 2007
Progen Expands Senior Management Team with Addition of Two Biopharmaceutical Industry Veterans
Progen Expands Senior Management Team with Addition of Two Biopharmaceutical Industry Veterans
HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
HSMN NewsFeed - 15 May 2007
Cougar Biotechnology Announces Additions to Clinical Research and Development Team
Cougar Biotechnology Announces Additions to Clinical Research and Development Team
HSMN NewsFeed - 8 May 2007
Biogen Idec and Vernalis Plc Announce the Start of Phase II Program of BIIB014 in Parkinson's Disease
Biogen Idec and Vernalis Plc Announce the Start of Phase II Program of BIIB014 in Parkinson's Disease
HSMN NewsFeed - 16 Mar 2007
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
HSMN NewsFeed - 12 Mar 2007
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
HSMN NewsFeed - 6 Mar 2007
Oncologic Appoints Stephen T. Isaacs as President and Chief Executive Officer
Oncologic Appoints Stephen T. Isaacs as President and Chief Executive Officer
HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed - 9 Jan 2007
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
HSMN NewsFeed - 21 Nov 2006
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
Altus Pharmaceuticals Appoints Shire Executive David Pendergast to Board of Directors
HSMN NewsFeed - 20 Nov 2006
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
HSMN NewsFeed - 20 Oct 2006
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
HSMN NewsFeed - 29 Sep 2006
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
HSMN NewsFeed - 20 Jul 2006
Poniard Pharmaceuticals Appoints Alan B. Glassberg, M.D., as Chief Medical Officer
Poniard Pharmaceuticals Appoints Alan B. Glassberg, M.D., as Chief Medical Officer
HSMN NewsFeed - 12 Jul 2006
Schering-Plough Announces Executive Changes in Schering-Plough Research Institute
Schering-Plough Announces Executive Changes in Schering-Plough Research Institute
HSMN NewsFeed - 6 Jul 2006
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed - 30 May 2006
Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis
Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
HSMN NewsFeed - 19 May 2006
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
HSMN NewsFeed - 17 May 2006
Cabrellis Pharmaceuticals Corporation Announces Corporate Launch and Founding Management Team
Cabrellis Pharmaceuticals Corporation Announces Corporate Launch and Founding Management Team
HSMN NewsFeed - 15 May 2006
Somaxon Pharmaceuticals Names Matthew Onaitis Vice President of Legal Affairs
Somaxon Pharmaceuticals Names Matthew Onaitis Vice President of Legal Affairs
HSMN NewsFeed - 8 May 2006
Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine
Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine
HSMN NewsFeed - 4 May 2006
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
Additional items found! 193

Members Archive contains
193 additional stories matching:
Biogen Idec
(Password required)
Biogen Idec
(Password required)